PARP1 and cervical carcinoma: Therefore, we speculate that PARP1 may be a potential target for CpG-ODNs in the treatment of RKI in cervical cancer, and CpG-ODNs may alleviate RKI in cervical cancer by downregulating PARP1 expression.